达利雷生(Quviviq)治疗失眠的效果

Introduction: It is a new anti-insomnia drug that is a dual orexin receptor antagonist. The drug shows positive effects in the treatment of chronic insomnia in adults, is well tolerated, and can quickly treat insomnia. DaliRasen should be taken under the guidance of a doctor, and the treatment plan should be adjusted according to the patient's specific conditions.

Therapeutic effect of DaliRasen

DaliRasen can significantly improve the patient's time to fall asleep, reduce the waking time after falling asleep, increase the total sleep duration, and improve sleep efficiency. These effects were shown to be significantly superior to placebo in clinical trials. In addition, DaliRasen not only improves nighttime sleep, it is also currently approved by the European Medicines Agency as a DORA insomnia drug that can improve daytime function, which has a positive impact on patients' daily quality of life and work ability.

Data in a phase III clinical study showed that after 1 and 3 months of treatment in patients with insomnia, Dalirasin significantly improved the patients' sleep onset, sleep maintenance, and self-reported total sleep time compared with placebo without changing the sleep structure.

Patients who took 50 mg of DaliRazen for more than three months were able to reduce the amount of time they spent awake each night by an average of 29 minutes, compared with 11 minutes for those taking a placebo. In addition, after 3 months of treatment, patients taking 50 mg of DaliRasen fell asleep about 35 minutes faster than before treatment, while patients taking a placebo fell asleep 23 minutes faster.

Medication Guide

Quviviq is only available by prescription and is available in tablet form. The recommended dose is one 50mg tablet taken within 30 minutes before going to bed at night. If your doctor thinks a lower dose is appropriate for you, you can take one 25 mg tablet at night. The effects of Quviviq may be delayed if taken with or immediately after a meal. Your doctor may recommend a lower dose if you have liver problems or take certain other medications. Treatment should be kept as short as possible and re-evaluated by a doctor within 3 months.

As a new type of anti-insomnia drug, DaliRasen has shown efficacy and good safety in clinical trials, making it an important choice for the treatment of chronic insomnia in adults. It is important to note that each patient's response may vary, and treatment effectiveness may be affected by the patient's specific condition, treatment history, and other health factors.